Long-term pegylated interferon study for HBV families with poor outcomes
Part of Cancer, Digestive system, Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study looks at how well pegylated interferon alpha-2b works over the long term for people with chronic hepatitis B who come from families where the virus has caused serious liver problems like cirrhosis or liver cancer. The goal is to see if this treatment can help prevent these bad outcomes in family members.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hepatitis B from a family where at least two generations have had the virus, and someone in your family has had cirrhosis or liver cancer.
- You have had hepatitis B surface antigen (HBsAg) in your blood for more than 6 months.
- You are currently taking or have taken nucleoside analogue pills for hepatitis B, or you have compensated cirrhosis due to hepatitis B.
- If you are a woman able to have children, you must have a negative pregnancy test before starting the study treatment.
- You must not have any medical reason that would make interferon treatment unsafe for you.
- You cannot have liver cancer or other cancers, and your blood counts and liver function must be within certain safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a long-acting interferon medication can help people with chronic hepatitis B who have already received interferon treatment clear the hepatitis B virus more completely. It's designed for patients whose virus levels dropped significantly during their first treatment but haven't gone away.
This trial studies whether pegylated interferon can help people with inactive chronic hepatitis B stay stable or improve outcomes. You may qualify if your virus levels and liver blood tests are currently low and you’ve never used antiviral treatments.
This study tests whether combining peginterferon alpha-2b with a nucleoside analog can lower liver cancer risk in people with chronic hepatitis B who have a family history of liver cancer. It compares the combination therapy to nucleoside analog alone.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
Hear when a new Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.